Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Polatuzumab successfully bridged 51% of patients to CAR-T in this retrospective study with a 6 months OS of

  • Polatuzumab successfully bridged 51% of patients to CAR-T in this retrospective study with a 6 months OS of 77.9%.